Formulation and purification of therapeutic dose of 90Y-labeled peptides: Some interesting radiochemistry aspects.

[1]  J. Buscombe,et al.  Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms. , 2016, Future oncology.

[2]  R. Baum,et al.  Peptide receptor radionuclide therapy with 90Y/177Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours) , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  DashAshutosh,et al.  Peptide Receptor Radionuclide Therapy: An Overview , 2015 .

[4]  L. Mariani,et al.  Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Rubel Chakravarty,et al.  Availability of yttrium-90 from strontium-90: a nuclear medicine perspective. , 2012, Cancer biotherapy & radiopharmaceuticals.

[6]  Rubel Chakravarty,et al.  Development of an electrochemical 90 Sr-90 Y generator for separation of 90 Y suitable for targeted therapy. , 2008, Nuclear medicine and biology.

[7]  M. Pillai,et al.  Extraction paper chromatography technique for the radionuclidic purity evaluation of 90Y for clinical use. , 2008, Analytical chemistry.

[8]  M. Cremonesi,et al.  Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  R. T. Steele,et al.  Large-scale purification of 90Sr from nuclear waste materials for production of 90Y, a therapeutic medical radioisotope. , 2003, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[10]  G. Denardo,et al.  Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.